+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Peramivir"

Influenza Medication - Global Strategic Business Report - Product Thumbnail Image

Influenza Medication - Global Strategic Business Report

  • Report
  • May 2024
  • 196 Pages
  • Global
From
From
H3N2 infection - Pipeline Insight, 2024 - Product Thumbnail Image

H3N2 infection - Pipeline Insight, 2024

  • Drug Pipelines
  • February 2024
  • 80 Pages
  • Global
From
From
Antiviral Therapeutics - Technologies, Markets & Companies - Product Thumbnail Image

Antiviral Therapeutics - Technologies, Markets & Companies

  • Report
  • November 2021
  • 620 Pages
  • Global
From
  • 11 Results (Page 1 of 1)
Loading Indicator

Peramivir is an antiviral drug used to treat a variety of infectious diseases. It is a neuraminidase inhibitor, meaning it works by blocking the activity of the neuraminidase enzyme, which is essential for the spread of the virus within the body. Peramivir is used to treat influenza, including both seasonal and pandemic strains, as well as other viral infections such as respiratory syncytial virus (RSV). It is administered intravenously and is generally well tolerated, with few side effects. Peramivir is approved for use in several countries, including the United States, Japan, and South Korea. It is also available in some countries as an investigational drug. In the United States, it is approved for use in adults and children over two years of age. The market for Peramivir is growing as the need for effective treatments for infectious diseases increases. It is a promising drug for the treatment of influenza and other viral infections, and its use is likely to expand in the future. Companies in the Peramivir market include Shionogi & Co., Ltd., BioCryst Pharmaceuticals, Inc., and Daewoong Pharmaceutical Co., Ltd. Show Less Read more